Simmons & Simmons JWS advises NSI Ventures and Aviva Ventures on investment into health-tech startup Biofourmis
31 Jan 2018
Simmons & Simmons JWS has advised NSI Ventures and Aviva Ventures on a US$5m Series A investment into Biofourmis Pte. Ltd., a health-tech company based in Singapore.
Biofourmis has developed a sophisticated health analytics platform which utilises artificial intelligence in analysing data to predict a medical patient’s health. If the patient’s health is deteriorating, the platform alerts medical professionals to intervene before a critical event.
The investment from NSI Ventures and Aviva Ventures will be deployed to fund the growth of Biofourmis into international markets.
NSI Ventures is a leading venture capital fund based in Singapore that focuses on Series A and B investments in technology companies within South East Asia. Key areas of investment for NSI Ventures include healthtech, fintech, edutech, consumer applications, cloud-based solutions and smart hardware. NSI Ventures is currently investing out of its second fund.
Aviva Ventures, the corporate venture arm of Aviva plc, aims to invest £100m by 2020 in early stage businesses worldwide. With offices in UK and Singapore, Aviva Ventures targets investments in digital and technology companies operating in four areas: ‘the internet of things’ including connected homes, health and automotives; data and analytics; innovative customer experiences; and distribution such as new ‘sharing economy’ platforms.
Simmons & Simmons JWS advised on all aspects of the transaction and fielded a Singapore-based team, comprising Damian Adams, Kelvin Goh, Kim Farrar, Calvin Tan, Justin Kwek and Colleen Cheong, with support from London-based IP partner Angus McLean.